A newly developed biosensor that can rapidly detect and quantify levels of dopamine — a chemical messenger nerve cells use to communicate — may serve as a low-cost and efficient tool to diagnose and monitor
Parkinsons Articles
Blood DNA methylation profiles may rate Parkinson’s dementia risk
Understanding and identifying epigenetic changes — those that affect gene activity without altering a gene’s DNA sequence — in blood samples from people with Parkinson’s disease and other neurological conditions may help assess the risk
Phase 1 trial of investigational therapy ALX-001 doses first patient
A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given
Mood, cognition issues tied to deficit recognizing, describing emotions
Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a
![[PODCAST] The Parkinson’s Podcast Unfiltered: Five and a Half Common Questions](https://www.shufflernews.com/wp-content/uploads/2024/05/dpf_favicon-1-400x250.png)
[PODCAST] The Parkinson’s Podcast Unfiltered: Five and a Half Common Questions
In this episode of the Parkinson’s Podcast Unfiltered, Heather and Kat answer some of the questions about Parkinson’s they hear most frequently. Listen in to hear …
Mechanism to weaken unused brain connections affected in Parkinson’s
The brain weakens unused neural connections in the striatum, a region involved in motor control and decision-making, through a nitric oxide-dependent mechanism that appears to be disrupted in Parkinson’s disease, a study in mice suggests.
Acute kidney injury raises risk of dementia, including in Parkinson’s
Having acute kidney injury increases the risk of developing dementia, including Parkinson’s disease with dementia, according to a study that suggests that people with kidney damage may benefit from close monitoring for early detection of
Dementia guide for home care workers set for trial
Home care provider VMCH has partnered with Caladenia Dementia Care and My Dementia Companion to develop and trial Australia’s
What’s New in Parkinson’s: August 2024
The FDA’s approval of Crexont®. Adaptive deep brain stimulation and DBS-Plus. New data on Parkinson’s-related dementia. Carbon monoxide’s protective powers. Here’s the latest …
Gain readies for Phase 1b trial of Parkinson’s therapy GT-02287
GT-02287, an oral small molecule from Gain Therapeutics, was found to be safe and well tolerated in healthy volunteers. It was also able to reach its target area, the brain, showing it has potential as
Rebrain’s AI software to optimize brain targeting approved by FDA
The U.S. Food and Drug Administration (FDA) has again cleared Rebrain’s OptimMRI software, this time including a new machine learning model to assist in targeting specific brain regions for lesioning techniques such as MR-guided focused
![[Webinar Recording] Live Well Today: Parkinson’s Subtypes](https://www.shufflernews.com/wp-content/uploads/2024/08/dr.-espay-headshot-300x300-1-300x250.png)
[Webinar Recording] Live Well Today: Parkinson’s Subtypes
In August’s Live Well Today webinar, neurologist Alberto Espay, MD, discussed Parkinson’s subtypes, why they are important, and what they mean for people living with Parkinson’s …